<DOC>
	<DOCNO>NCT01952561</DOCNO>
	<brief_summary>Study evaluate vaginal blood pharmacokinetics dapivirine vaginal ring contain 25 mg worn 1 , 2 , 4 , 8 12 month .</brief_summary>
	<brief_title>Expanded Use PK Dapivirine Vaginal Ring</brief_title>
	<detailed_description />
	<criteria>Key 1 . Women 18 â‰¤ 40 year age give write informed consent 2 . Available visit consent follow procedure schedule trial 3 . Healthy , base medical history , vital sign , physical examination , urinalysis , laboratory evaluation genital infection , laboratory evaluation haematology chemistry 4 . HIVnegative determine HIV test time enrolment 5 . On stable form contraception , define : A stable oral contraceptive regimen least 2 month prior enrolment , OR Transdermal contraceptive patch least 3 month prior enrolment , OR Longacting progestin least 6 month prior enrolment , OR An IUD insert least 3 month prior enrolment , OR Have undergone surgical sterilisation least 3 month prior enrolment AND willing use oral contraceptive necessary delay menstruation vaginal sampling period 6 . Upon pelvic examination time enrolment , cervix vagina appear normal determined Investigator/Physician 7 . Asymptomatic genital infection time enrolment 8 . Willing refrain use topical vaginal medication , vaginal product object 9 . Documentation abnormality cervical cytology , include grossly bloody smear , within 90 day prior screen 10 . Willing refrain participation research trial duration trial 11 . Willing provide adequate locator information trial retention purpose reachable per local standard procedure , e.g . home visit telephone , via family close neighbour contact 12 . Willing agree abstain follow total 2 day ( 48 hour ) prior trial visit : Penilevaginal intercourse Oral contact genitalia 13 . Hepatitis B C negative time enrolment . Key 1 . Currently pregnant last pregnancy outcome within 3 month prior screen 2 . Currently breastfeed 3 . Currently within two month participation clinical research trial involve investigational market product prior screen 4 . Untreated symptomatic urogenital infection , e.g . urinary tract sexually transmitted infection , gynaecological condition vaginal itching , pain , discharge , within 2 week prior enrolment 5 . Have Grade 2 high pelvic examination finding , accord DAIDS Table Grading Severity Adult Pediatric Adverse Events ; 6 . History significant urogenital uterine prolapse , undiagnosed vaginal bleeding , urethral obstruction , incontinence urge incontinence 7 . Current vulvar vaginal symptoms/abnormalities could influence trial result 8 . Cervical cytology screen require cryotherapy , biopsy , treatment ( infection ) , evaluation 9 . Symptomatic genital herpes simplex virus ( HSV ) infection history genital herpetic infection 10 . Any Grade 2 , 3 4 haematology , biochemistry urinalysis laboratory abnormality baseline ( screen ) accord DAIDS Table Grading Severity Adult Pediatric Adverse Events ; 11 . Unexplained , abnormal bleed per vagina follow vaginal intercourse , gynaecologic surgery within 90 day prior enrolment 12 . Any history anaphylaxis severe allergy result angioedema ; history sensitivity/allergy latex silicone 13 . Any serious acute , chronic progressive sign cardiac disease , renal failure , severe malnutrition 14 . Have undergone hysterectomy 15 . Any condition ( ) , opinion Investigator , might interfere adherence trial requirement evaluation trial objective .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>pharmacokinetics</keyword>
	<keyword>vaginal ring</keyword>
</DOC>